experimental vaccine (Meningococcal disease Vaccine)

Category Resource

Explore licensed vaccines, adverse event reporting data, and history for this disease.

View Meningococcal disease Vaccine Guide →

Development Phase Phase 3 Clinical Trial Primary Status

Platform Technology Conjugate vaccine Biologic Architecture

Target Indication Meningococcal disease Pathogen / Antigen

Last Verified 2026-07-10 Tier 1 Multi-Source Checked

Multi-Jurisdiction Regulatory Status

Official licensing, rolling submissions, or authorization status tracked across major health authorities.

Regulatory Authority	Status & Details
US FDA	Not Filed / Pre-submission
EMA (Europe)	Not Filed / Pre-submission
Health Canada	Not Filed / Pre-submission
TGA (Australia)	Not Filed / Pre-submission

Scientific Profile & Documentation

Platform Architecture: Conjugate vaccine
Lead Developer: Sinovac Biotech Co., Ltd
Next Expected Milestone: Primary completion (most advanced trial): 2026-11 (registry estimate)
Analyst & Development Notes: Auto-grouped from 4 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.
Primary Source Documentation: ClinicalTrials.gov NCT07505888 →
Additional Sources & Literature: NCT07505836 on ClinicalTrials.gov (2026-07-10)
NCT07505823 on ClinicalTrials.gov (2026-07-10)
NCT07505810 on ClinicalTrials.gov (2026-07-10)

Registered Clinical Trials & Studies

Direct registry links to active, completed, or pivotal registration studies across phases.

NCT07505888 Phase 3 Clinical Trial

Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years

Status: Active / Ongoing • Expected Readout: 2026-11

NCT07505836 Phase 3 Clinical Trial

Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 Months

Status: Active / Ongoing • Expected Readout: 2027-01

NCT07505823 Phase 3 Clinical Trial

Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 6-11 Months

Status: Active / Ongoing • Expected Readout: 2027-04

NCT07505810 Phase 3 Clinical Trial

Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 3-5 Months

Status: Active / Ongoing • Expected Readout: 2027-04

Milestone Overview

Stage Verification

Phase 3 Clinical Trial confirmed as of 2026-07-10.
Target Milestone

Primary completion (most advanced trial): 2026-11 (registry estimate)

Vaccine Data Navigator Candidate Profile Registry:

This candidate profile is indexed across all clinical development levels (Preclinical through Phase 1–3, Regulatory Filing, and Licensure) from primary registry databases (ClinicalTrials.gov, WHO ICTRP, FDA CBER, EMA, Health Canada, TGA Australia). Data are updated continuously to track global biologic and vaccine pipelines.